Trials / Completed
CompletedNCT01323751
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1(a \& b): To evaluate the side effects and determine the best dose of oral ACY-1215 as monotherapy, and also in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Phase 2a: To determine the objective response rate of oral ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACY-1215 | Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-03
- First posted
- 2011-03-28
- Last updated
- 2017-04-06
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01323751. Inclusion in this directory is not an endorsement.